PlainRecalls
FDA Drug Critical Class I Terminated

Mirtazapine Tablets, USP, 7.5 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-001-05

Reported: December 18, 2019 Initiated: November 20, 2019 #D-0637-2020

Product Description

Mirtazapine Tablets, USP, 7.5 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-001-05

Reason for Recall

Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.

Details

Recalling Firm
AuroMedics Pharma LLC
Units Affected
N/A
Distribution
Nationwide
Location
East Windsor, NJ

Frequently Asked Questions

What product was recalled?
Mirtazapine Tablets, USP, 7.5 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-001-05. Recalled by AuroMedics Pharma LLC. Units affected: N/A.
Why was this product recalled?
Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 18, 2019. Severity: Critical. Recall number: D-0637-2020.